An observational prospective study was performed on 35 women with breast cancer with an active CDK4/6i treatment in combination with endocrine therapy, who were scheduled to receive the mRNA-1273 SARS-CoV-2 vaccine. The gene discussed is CDK4; the disease is breast carcinoma.